UCLA Health Jonsson Comprehensive Cancer Center

Latest from UCLA Health Jonsson Comprehensive Cancer Center


Frontline Pembrolizumab Plus Chemo Does Not Show Superior OS Over Chemo Alone in PD-L1+ Gastric/GEJ Adenocarcinoma

January 21, 2022

Pembrolizumab plus chemotherapy did not induce clinically meaningful survival benefit, compared with chemotherapy alone, in patients with advanced gastric or gastroesophageal junction adenocarcinoma and a PD-L1 combined positive score of 1 or higher.